Art + Cultural and Creative Products Giving New Life to Cultural Relics
17.11.2022 12:56:00 EET | Business Wire | Press release
An international themed achievement exhibition of “THE BIG DRAW ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was held at the Sanxingdui Museum on November 16, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116006124/en/
(Photo: Business Wire)
“THE BIG DRAW, UK Arts Charity launched ‒ Ar[t]chaeology: Convergence of Art with Sanxingdui” was co-hosted by Sichuan Provincial Department of Culture and Tourism, Deyang Municipal People’s Government, Sichuan Provincial Cultural Heritage Administration, and Hong Kong Trade Development Council; co-organised by Sichuan Publicity Information Center for Culture and Tourism, Sichuan Provincial Academy of Arts, and Management Committee of Sanxingdui Museum; supported by Sichuan Provincial Cultural Relics and Archaeology Research Institute and Deyang Municipal Bureau of Culture, Radio, TV and Tourism. Since the event was launched in June 2022, it has attracted 33 renowned artists from 22 countries and regions and nearly 2,000 participants from over 80 schools and universities.
Yan Sashuang, Vice Director General of Sichuan Provincial Department of Culture and Tourism, presided over the event of the themed achievement exhibition. Dai Yunkang, Vice Director General of the Publicity Department of the CPC Sichuan Provincial Committee, addressed the event. Dai pointed out that Sichuan is a renowned tourist destination in China for its unique Ba-Shu culture and ancient Shu culture. This event attracted artists, art lovers and children worldwide to portray Sanxingdui in their eyes, breathing new life into cultural relics.
He Ping, vice mayor of Deyang Municipal People’s Government, said this event significantly promoted the creative inheritance of Sanxingdui culture and opened a new chapter in the innovative application of cooperation outcomes.
Jacky Chung, Director of the Chinese mainland of Hong Kong Trade Development Council, pointed out that the event is another proof of the in-depth cooperation between Sichuan’s museums and cultural institutions and Hong Kong-funded enterprises.
Kam Panesar, The Big Draw Brand Ambassador in China said, “The UK's expertise in museum and galleries culture and creative tourism is world class. Together with Sichuan Provisional Bureau for Culture and Tourism is an ingrained part of the UK's Arts & Cultural knowledge to implement people centred cultural and artistic festivals in both the UK and China.”
Sanxingdui Culture and Tourism Development Co., Ltd. and BRDGS Partners Group signed an agreement on cultural and creative products cooperation at the site.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116006124/en/
Contact information
Sichuan Provincial Department Of Culture and Tourism
Lai Cheuk Fay
ylai18200130301@163.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom